Predictive Health Diagnostics Company's Proprietary Computational Technology Enables Development of Specialty Diagnostic Tests to Improve Patient Care
IRVINE, Calif., June 1, 2021 /PRNewswire/ -- Predictive Health Diagnostics Company, Inc. ("PHDC" or "the Company"), a diagnostics development platform company that develops, manufactures, and distributes specialty diagnostic tests combining science, technology, and proprietary analytics to detect diseases with significant unmet medical needs, today announced its business strategy and development plan, including upcoming corporate milestones.
"PHDC's diagnostic tests combine cutting-edge science with the most effective technology to conquer some of the biggest challenges in healthcare," said Matthew Nuñez, Chief Executive Officer of Predictive Health Diagnostics Company. "We launched our lead cardiovascular test, the PULS Cardiac Test™, in 2018, and we reached a major milestone in December 2020 with our 100,000th test order. Heart disease is 80% preventable, and with the PULS Cardiac Test, we offer a one-of-a-kind, non-invasive way to detect the underlying risk of a heart attack early on, when prevention is most effective. We will soon execute the rollout of our other pipeline products in diabetes and oncology. Next will be DIABETESpredict™, a new way to intervene in Type 2 diabetes by identifying risk – even before symptoms or abnormal tests."
"Our team has spent the last three years creating an industry-leading diagnostics development platform that gives us the unmatched ability to innovate," Nuñez continued. "Utilizing our proprietary computational technology, PHDC goes from data to realized diagnostic test with greater speed and lower development costs than our closest competitors in the diagnostics market."
The PULS Cardiac Test™
Currently, the PULS Cardiac Test may be ordered and administered by healthcare providers. A new fingerstick collection device, presently in late-stage development, will be marketed via several new distribution channels with launch planned for later this year.
PHDC has also developed a PULS Cardiac Test kit for distribution through clinical laboratories. The Company is planning an FDA pre-submission for this product in June 2021, and the FDA's clinical validation process is scheduled to begin thereafter.
Successful licensing of DIABETESpredict was completed in late 2020, and commercial launch is expected in June 2021.
Commercializing Laboratory Developed Tests (LDTs) via the CLIA (Clinical Laboratory Improvement Amendments) regulatory process
Licensing LDTs to strategic partners
Intellectual Property Strategy
About Predictive Health Diagnostics Company
Forward-looking statements are based on our current expectations and assumptions regarding our business, our industry, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you therefore against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance.
Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
View original content to download multimedia:http://www.prnewswire.com/news-releases/predictive-health-diagnostics-companys-proprietary-computational-technology-enables-development-of-specialty-diagnostic-tests-to-improve-patient-care-301303359.html
SOURCE Predictive Health Diagnostics Company